Teladoc, Inc. (TDOC) Receives Hold Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their hold rating on shares of Teladoc, Inc. (NYSE:TDOC) in a report issued on Monday morning. The firm currently has a $27.00 target price on the health services provider’s stock.

“Strategy makes sense. Boston-based Best Doctors is a medical consultation company focused on second opinions. Its primary customer base lines up nicely with that of TDOC in that it offers cost-containment solutions to employers and payer/provider solutions. In addition to offering expert medical reviews, it provides potential physician referrals to members. With Best Doctors, TDOC expands its range of services into higher-acuity (costs) healthcare delivery. Strategically, the combination of Best Doctors and TDOC makes sense to us. Financials are a different story. TDOC indicates that Best Doctors is expected to generate revenue in excess of $100 million in 2017. This compares with Best Doctors’ 2016 revenue of $92 million (net of divestitures). Our standalone TDOC revenue estimate is $182.5 million for 2017. On an annualized basis, Best Doctors generates about $8.8 million of adjusted EBITDA. TDOC’s 2017 adjusted EBITDA guidance prior to the acquisition was a loss of $19.5-22.5 million. Although Best Doctors should be immediately additive to TDOC’s adjusted EBITDA, added interest expense and more shares outstanding will likely result in a slightly higher loss per share in 2018, before any revenue and cost synergies. Before synergies, the EV/EBITDA valuation for Best Doctors is about 50x (on a run-rate basis), which is expensive.”,” Cantor Fitzgerald’s analyst commented.

A number of other research analysts have also recently commented on TDOC. Robert W. Baird reiterated an outperform rating and issued a $33.00 price objective (up from $28.00) on shares of Teladoc in a report on Friday. Cowen and Company upped their price objective on Teladoc from $29.00 to $36.00 and gave the company an outperform rating in a report on Wednesday, May 31st. Oppenheimer Holdings, Inc. set a $27.00 price objective on Teladoc and gave the company a buy rating in a report on Thursday, March 2nd. Chardan Capital upped their price objective on Teladoc from $28.00 to $30.00 and gave the company a buy rating in a report on Tuesday, May 9th. Finally, CIBC upped their price objective on Teladoc from $27.00 to $40.00 and gave the company an outperform rating in a report on Monday, June 12th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Teladoc has an average rating of Buy and an average target price of $32.77.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Shares of Teladoc (TDOC) traded down 5.73% during midday trading on Monday, hitting $33.75. The stock had a trading volume of 1,106,557 shares. Teladoc has a 52-week low of $12.31 and a 52-week high of $35.90. The firm’s market cap is $1.84 billion. The firm’s 50 day moving average price is $29.79 and its 200 day moving average price is $23.20.

Teladoc (NYSE:TDOC) last released its quarterly earnings data on Monday, May 8th. The health services provider reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. Teladoc had a negative return on equity of 24.73% and a negative net margin of 53.58%. The firm had revenue of $42.90 million for the quarter, compared to analysts’ expectations of $42.22 million. During the same period in the prior year, the firm posted ($0.40) earnings per share. The firm’s quarterly revenue was up 59.5% on a year-over-year basis. On average, equities research analysts expect that Teladoc will post ($0.88) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/2655723/teladoc-inc-tdoc-receives-hold-rating-from-cantor-fitzgerald.html.

In other Teladoc news, CEO Jason N. Gorevic sold 19,991 shares of the company’s stock in a transaction on Tuesday, June 6th. The stock was sold at an average price of $32.89, for a total transaction of $657,503.99. Following the transaction, the chief executive officer now directly owns 831,650 shares in the company, valued at $27,352,968.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jason N. Gorevic sold 13,389 shares of the company’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $32.89, for a total value of $440,364.21. Following the transaction, the chief executive officer now owns 831,650 shares in the company, valued at $27,352,968.50. The disclosure for this sale can be found here. Insiders have sold 232,480 shares of company stock worth $6,439,354 over the last 90 days. 5.94% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its stake in Teladoc by 163.5% in the first quarter. FMR LLC now owns 8,103,237 shares of the health services provider’s stock worth $202,581,000 after buying an additional 5,028,237 shares in the last quarter. Wellington Management Group LLP raised its stake in Teladoc by 38.9% in the first quarter. Wellington Management Group LLP now owns 4,228,082 shares of the health services provider’s stock worth $105,701,000 after buying an additional 1,183,435 shares in the last quarter. Vanguard Group Inc. raised its stake in Teladoc by 50.0% in the first quarter. Vanguard Group Inc. now owns 2,727,079 shares of the health services provider’s stock worth $68,177,000 after buying an additional 909,252 shares in the last quarter. Alliancebernstein L.P. raised its stake in Teladoc by 211.1% in the first quarter. Alliancebernstein L.P. now owns 2,286,200 shares of the health services provider’s stock worth $57,155,000 after buying an additional 1,551,315 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Teladoc by 8,826.7% in the first quarter. JPMorgan Chase & Co. now owns 1,606,535 shares of the health services provider’s stock worth $40,163,000 after buying an additional 1,588,538 shares in the last quarter. Institutional investors own 94.26% of the company’s stock.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “TDOC”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.